Rapt Therapeutics $RAPT Shares Sold by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. cut its holdings in Rapt Therapeutics (NASDAQ:RAPT) by 21.8% during the third quarter, Holdings Channel reports. The institutional investor owned 344,237 shares of the company’s stock after selling 95,939 shares during the quarter. Rapt Therapeutics comprises 1.8% of Fcpm Iii Services B.V.’s investment portfolio, making the stock its 8th biggest holding. Fcpm Iii Services B.V.’s holdings in Rapt Therapeutics were worth $8,878,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of RAPT. Bridgeway Capital Management LLC lifted its holdings in Rapt Therapeutics by 32.0% in the third quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock valued at $532,000 after acquiring an additional 5,000 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Rapt Therapeutics during the 3rd quarter worth $231,000. UBS Group AG increased its holdings in shares of Rapt Therapeutics by 680.3% in the 3rd quarter. UBS Group AG now owns 28,808 shares of the company’s stock valued at $743,000 after purchasing an additional 25,116 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Rapt Therapeutics by 411.7% in the 1st quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock valued at $72,000 after purchasing an additional 47,391 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Rapt Therapeutics in the third quarter valued at about $1,326,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on RAPT shares. TD Cowen downgraded shares of Rapt Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 20th. Wall Street Zen raised shares of Rapt Therapeutics to a “hold” rating in a report on Saturday, March 7th. Guggenheim downgraded shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. HC Wainwright lowered Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price target on the stock. in a research note on Tuesday, January 20th. Finally, Piper Sandler cut Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 price target on the stock. in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Rapt Therapeutics currently has an average rating of “Hold” and an average price target of $48.44.

Rapt Therapeutics Price Performance

Rapt Therapeutics stock opened at $58.02 on Monday. Rapt Therapeutics has a 52 week low of $5.67 and a 52 week high of $58.02. The firm’s 50-day simple moving average is $52.37 and its 200 day simple moving average is $36.33. The firm has a market capitalization of $1.61 billion, a PE ratio of -5.25 and a beta of 0.49.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.